MA38066A1 - Dérivés d'exendine-4 utilisés en tant qu'agonistes doubles de glp1/glucagon - Google Patents
Dérivés d'exendine-4 utilisés en tant qu'agonistes doubles de glp1/glucagonInfo
- Publication number
- MA38066A1 MA38066A1 MA38066A MA38066A MA38066A1 MA 38066 A1 MA38066 A1 MA 38066A1 MA 38066 A MA38066 A MA 38066A MA 38066 A MA38066 A MA 38066A MA 38066 A1 MA38066 A1 MA 38066A1
- Authority
- MA
- Morocco
- Prior art keywords
- exendin
- glp1
- double
- derivatives used
- glucagon agonists
- Prior art date
Links
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des dérivés d'exendine-4 et leur utilisation médicale, par exemple dans le traitement de troubles du syndrome métabolique, notamment le diabète et l'obésité, ainsi que la réduction d'une absorption excessive de nourriture.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306232 | 2012-10-09 | ||
| PCT/EP2013/070882 WO2014056872A1 (fr) | 2012-10-09 | 2013-10-08 | Dérivés d'exendine-4 utilisés en tant qu'agonistes doubles de glp1/glucagon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38066A1 true MA38066A1 (fr) | 2016-05-31 |
| MA38066B1 MA38066B1 (fr) | 2017-05-31 |
Family
ID=47143789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38066A MA38066B1 (fr) | 2012-10-09 | 2013-10-08 | Dérivés d'exendine-4 utilisés en tant qu'agonistes doubles de glp1/glucagon |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR105457A2 (fr) |
| MA (1) | MA38066B1 (fr) |
-
2013
- 2013-10-08 MA MA38066A patent/MA38066B1/fr unknown
-
2016
- 2016-07-22 AR ARP160102248A patent/AR105457A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38066B1 (fr) | 2017-05-31 |
| AR105457A2 (es) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38276B1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
| EA201590715A1 (ru) | Производные эксендина-4 как двойные агонисты glp1/глюкагона | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
| EA201590011A1 (ru) | Пептидные аналоги эксендина-4 | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| BR112013017314A2 (pt) | composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| EE05761B1 (et) | Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks | |
| EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
| EA201591123A1 (ru) | Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств | |
| MA38066B1 (fr) | Dérivés d'exendine-4 utilisés en tant qu'agonistes doubles de glp1/glucagon | |
| BR112015018930A2 (pt) | benzamidas substituídas com atividade para receptores ep4 | |
| WO2014014816A3 (fr) | Méthodes de traitement de troubles du métabolisme du glucose |